Browsing by Author "Kemppainen, Tommi"

Now showing 1 - 4 of 4

Design of a 1 GHz BiCMOS I/Q demodulator
(1996) Kemppainen, Tommi
Helsinki University of Technology | Master's thesis
Designing a legitimate value proposition for a new Finnish forest fund
(2022-10-19) Tervala, Elli
Perustieteiden korkeakoulu | Master's thesis
Legitimacy – being deemed desirable, proper, and appropriate – plays a central role for whether a venture will succeed or perish and therefore it is a central theme for strategic planning. For new ventures legitimacy hurdles are most numerous, but popular methodology for designing value propositions for startups does not address the concept of legitimacy. In this thesis I ask, how can legitimacy be considered when designing a new value proposition for an investment fund product. Empirical setting is forest funds in Finland, and it was chosen, because fund investing is growing more popular, forest funds are a new phenomenon in Finland and their legitimacy routinely gets scrutinized in the public space. To study the subject, this thesis is three-fold. First, I studied the incumbents in the category to understand, how they make claims about their legitimacy, and how these claims are distributed in pragmatic, normative, value-based, and cognitive legitimacy categories. From findings, a stereotype of a typical forest fund was formed. Second, a value proposition for a new product of the same category was designed, using lean startup approach and findings of the previous step. Finally, an audience was interviewed on the value proposition to validate whether the customers judged it legitimate or not. The audience judged the product cognitively legitimate, but the forest funds cate-gory was seen legitimate by only about 40% of the subjects. Socio-politically, the value proposition was judged legitimate as expected, biggest concern being that it does not differentiate enough from the incumbents to justify its existence, and it needs further refining to differentiate more. The study showed that legitimacy can be considered already in the design phase, but this does not eliminate the need for iterations. Perhaps, legitimacy could complement the existing lean startup method and a complete new “legitimacy design canvas”-tool could be created to help operationalize the idea. Designing for legitimacy has potential to decrease the number of iterations needed to build a viable offering and therefore it could also mean a faster time to market.
PK-yrityksen sähköisen liiketoiminnan tason mittaaminen
(2013-02-25) Ilomäki, Juuso
Perustieteiden korkeakoulu | Bachelor's thesis
Strategic choices for growth among European midsized pharmaceutical companies
(2008) Kemppainen, Tommi
Helsinki University of Technology | Master's thesis
The purpose of the study is to identify the most important strategic choices for pharmaceutical companies and to understand how they affect the financial success of the company. The research problem is stated as follows: "What are the corporate strategies that have led to a financial success among midsized European pharmaceutical companies?" The study has an explorative approach to the subject. The framework for the study identifies four groups of indicators: knowledge acquisition methods, business orientation, complementary assets or businesses and product portfolio. The financial success is evaluated based on growth of sales and market value and profitability. Quantitative and qualitative data is collected from commercial databases and annual reports. The sample of the study is 62 companies. The breadth and volume of product portfolio explains most of the variation between the behaviors of companies. The companies are classified into three strategic groups: Performers that have a drive for a strong product portfolio, passives that are passive in most of the indicators, and individualists that are very active in their chosen unique strategy. Large companies are more active and have grown faster than small ones. The most important factors explaining the financial success are the volume of acquisitions and the strength of a company's product portfolio, which can be either developed in-house or in-licensed. Activity on product factor is beneficial but does not guarantee success. There are differences between companies based on their business models. Patenting and alliances seem to have no relationship with financial success but acquisitions and licensing might enhance growth. Also the use of complementary assets or businesses seems to have little significance. Profitability of a pharmaceutical company has no observable impact on its market value. This study sheds light on the sources for financial success and growth of midsized pharmaceutical companies. It reveals differences to existing literature and raises concern for validity of widely recognized metrics for internal development and their impact on financial success in this target group. The model is a useful cognitive tool for management and it applies best for companies focused on R&D or biotechnology.